Page last updated: 2024-12-08

my 1250

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MY 1250: structure given in first source; an active metabolite of the prodrug repirinast (BAY u 2372) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID152032
SCHEMBL ID2994308
SCHEMBL ID11385272
MeSH IDM0141759

Synonyms (11)

Synonym
bay w 8199
7,8-dimethyl-4,5-dioxo-6h-pyrano[3,2-c]quinoline-2-carboxylic acid
4h-pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-
my-1250
63768-47-8
my 1250
SCHEMBL2994308
SCHEMBL11385272
DTXSID00213214
J-519061
7,8-dimethyl-4,5-dioxo-5,6-dihydro-4h-pyrano[3,2-c]quinoline-2-carboxylic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" MY-1250 had no effect on the norepinephrine-induced dose-response curve in isolated rat aorta."( [Cardiovascular effects of MY-5116 and MY-1250].
Hanazuka, M; Hara, Y; Horii, D; Nishi, H, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (46.15)18.7374
1990's6 (46.15)18.2507
2000's1 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.03 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (17.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.69%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]